Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line - Immunotherapy

No Prior Therapy With PD-1/PD-L1
- LUN0085
  Phase II
  Pembrolizumab in Metastatic Non-Squamous NSCLC
  Examining Circulating Tumor DNA Levels
  PI: Neal Stanford
  1st Priority

On anti PD-1/ anti PD-L1 with response, stable disease or modest progression
- LUN0093
  Phase II
  NKTR-214 + Nivolumab in Select Locally Advanced or Metastatic Solid Tumor Malignancies
  PI: Neal Nektar
  2nd Priority

Failed Therapy PD-L1
- LUN0107
  Phase Ib/Ii
  Grapiprant +/- Pembrolizumab in Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
  PI: Wakelee Amys Therapeutics

KEY
- Pending
- Open for Enrollment
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Optional Path
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu